cdk2 inhibitor eci830
Generic: CDK2 Inhibitor ECI830
cdk2 inhibitor eci830: 1 clinical trial tracked.
cdk2 inhibitor eci830 evidence translation
What we can confirm
1 tracked trial
No verified listed company relationship
What it means
AI will separate confirmed drug evidence from unknown company context.
What to watch
Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected
Prepared research question
What is verified about cdk2 inhibitor eci830, and what remains unknown?
Run cited research
Traceable citations · Unknowns marked
Clinical Trial Registry Records (1)
An Open-label, Multi-center, Phase I/II Study of ECI830 as a Single Agent and in Combination With Ribociclib and Endocrine Therapy in Patients With Advanced Hormone Receptor Positive, HER2-negative Breast Cancer and Advanced Solid Tumors
Primary endpoint: Phase I: Incidence of dose-limiting toxicities (DLTs)
InterventionalRandomizedopen280 targetStarted 2025-04Completion 2028-0933 sites · Australia, Canada, China, Czechia…Novartis Pharmaceuticals